Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zafgen Inc (ZFGN)

Zafgen Inc (ZFGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zafgen Inc 3 Center Plaza Suite 610 BOSTON MA 02108 USA

www.zafgen.com P: 617-622-4003

Description:

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 37,095
Shares Outstanding, K 37,470
Annual Sales, $ 0 K
Annual Net Income, $ -45,410 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,600 K
60-Month Beta 0.27
% of Insider Shareholders 14.20%
% of Institutional Shareholders 70.43%
Float, K 32,149
% Float 85.80%

Growth:

1-Year Return -62.78%
3-Year Return -73.39%
5-Year Return -97.01%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 64.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/14/20
Earnings Per Share ttm -0.81
EPS Growth vs. Prev Qtr 33.33%
EPS Growth vs. Prev Year 71.43%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 05/29/20

ZFGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -51.34%
Return-on-Assets % -34.55%
Profit Margin % 0.00%
Debt/Equity 0.26
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.73
Book Value/Share 1.35
Interest Coverage -24.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar